Best in Class Case Study- Big Data & Cancer Research

We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights click here. By clicking the "Download button" you agree to the terms of our Privacy Policy.

  As of now, big data is not utilised as often and as well as it could be in the Pharmaceutical Industry.Data usage could lead to accelerated drug discovery and better help patients, enabling companies to streamline, become more productive, more efficient, and reduce costs. Allan Jordan strongly believes that while big data is important and can change Pharma, it should not just be gathered without reason. There needs to be a purpose, and purpose is the main thing driving his latest project.


The project in question is focused on exploiting genome sequencing efforts to discover new targets for cancer treatment. Allan and his team are working to combine unexploited genomic data with a new concept called collateral vulnerability to try and find weaknesses within tumour cells. This is a huge opportunity for positive change. The goal is finding treatments for cancer patients who haven’t had ideal responses to chemotherapy
Have Your Say
Rate this feature and give us your feedback in the comments section below